Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Terns Pharmaceuticals

Request full access

Biopharmaceutical company focused on discovering therapies that will improve the global disease burden

Foster City, United StatesFounded 2017Biotech & Life Sciences

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a portfolio of small-molecule drug candidates for serious diseases like oncology and obesity. The company was established in 2017 by co-founders Weidong Zhong, Martijn Fenaux, and Randall L. Halcomb. Dr. Zhong, an industry veteran with over two decades of experience in drug discovery at companies like Novartis and Gilead, sought to create a more nimble organization to develop innovative medicines, particularly for underserved markets. The company initially aimed to bridge drug discovery in the U.S. with accelerated clinical development in China but has since shifted its focus primarily to the U.S. market.

Headquartered in Foster City, California, Terns went public on the Nasdaq Global Select Market under the ticker symbol "TERN" on February 5, 2021, raising approximately $127.5 million in its initial public offering. The company operates as a clinical-stage entity, meaning its revenue generation model is based on the potential future commercialization of its drug candidates currently undergoing clinical trials. Its financial strategy involves securing funding through public offerings and strategic partnerships to support its extensive research and development activities. As of early 2025, Terns reported having a cash runway to fund its operations into 2028.

Terns' therapeutic pipeline includes several clinical-stage programs. A lead candidate is TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML), a type of bone marrow cancer. This oral drug candidate has received Orphan Drug Designation from the U.S. FDA and has shown promising molecular responses and a favorable safety profile in early trials. Another key program is TERN-601, a once-daily oral GLP-1 receptor agonist being developed for obesity. Phase 1 results for TERN-601 demonstrated weight loss and good tolerability. The pipeline also features TERN-501, a thyroid hormone receptor-beta (THR-β) agonist, being explored for metabolic diseases. The company's business model centers on advancing these candidates through the rigorous phases of clinical trials to gain regulatory approval and eventually bring new treatments to patients.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021

Terns Pharmaceuticals in the Foster City ecosystem

Live from Dealroom

The Terns Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Series B and later5 investors entered at this stage

  • Eli Lilly
  • Deerfield
  • Samara Capital
  • Suvretta Capital Management
  • Commodore Capital
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$54M

39 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Terns Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.